197 related articles for article (PubMed ID: 16414250)
21. An open-label, randomized, controlled trial of zotepine and risperidone for acutely ill, hospitalized, schizophrenic patients with symptoms of agitation.
Chan HY; Lin AS; Chen KP; Cheng JS; Chen YY; Tsai CJ
J Clin Psychopharmacol; 2013 Dec; 33(6):747-52. PubMed ID: 24100785
[TBL] [Abstract][Full Text] [Related]
22. Elderly patients with dementia-related symptoms of severe agitation and aggression: consensus statement on treatment options, clinical trials methodology, and policy.
Salzman C; Jeste DV; Meyer RE; Cohen-Mansfield J; Cummings J; Grossberg GT; Jarvik L; Kraemer HC; Lebowitz BD; Maslow K; Pollock BG; Raskind M; Schultz SK; Wang P; Zito JM; Zubenko GS
J Clin Psychiatry; 2008 Jun; 69(6):889-98. PubMed ID: 18494535
[TBL] [Abstract][Full Text] [Related]
23. Risperidone for the treatment of behavioral disturbances in dementia: a case series.
Herrmann N; Rivard MF; Flynn M; Ward C; Rabheru K; Campbell B
J Neuropsychiatry Clin Neurosci; 1998; 10(2):220-3. PubMed ID: 9608413
[TBL] [Abstract][Full Text] [Related]
24. The use of risperidone for psychosis and agitation in demented patients with Parkinson's disease.
Workman RH; Orengo CA; Bakey AA; Molinari VA; Kunik ME
J Neuropsychiatry Clin Neurosci; 1997; 9(4):594-7. PubMed ID: 9447503
[TBL] [Abstract][Full Text] [Related]
25. Long-term, open-label study of risperidone in children with severe disruptive behaviors and below-average IQ.
Findling RL; Aman MG; Eerdekens M; Derivan A; Lyons B;
Am J Psychiatry; 2004 Apr; 161(4):677-84. PubMed ID: 15056514
[TBL] [Abstract][Full Text] [Related]
26. Comparative efficacy of risperidone versus haloperidol on behavioural and psychological symptoms of dementia.
Suh GH; Greenspan AJ; Choi SK
Int J Geriatr Psychiatry; 2006 Jul; 21(7):654-60. PubMed ID: 16821257
[TBL] [Abstract][Full Text] [Related]
27. Relapse risk after discontinuation of risperidone in Alzheimer's disease.
Devanand DP; Mintzer J; Schultz SK; Andrews HF; Sultzer DL; de la Pena D; Gupta S; Colon S; Schimming C; Pelton GH; Levin B
N Engl J Med; 2012 Oct; 367(16):1497-507. PubMed ID: 23075176
[TBL] [Abstract][Full Text] [Related]
28. Risperidone in the management of disruptive behavior disorders.
Pandina GJ; Aman MG; Findling RL
J Child Adolesc Psychopharmacol; 2006 Aug; 16(4):379-92. PubMed ID: 16958564
[TBL] [Abstract][Full Text] [Related]
29. Don't use antipsychotics routinely to treat agitation and aggression in people with dementia.
Corbett A; Burns A; Ballard C
BMJ; 2014 Nov; 349():g6420. PubMed ID: 25368388
[No Abstract] [Full Text] [Related]
30. [Parenteral Antipsychotics in the Treatment of Agitation and Aggression].
Utzerath G; Reske D; Gouzoulis-Mayfrank E
Fortschr Neurol Psychiatr; 2015 Dec; 83(12):665-75. PubMed ID: 26714248
[TBL] [Abstract][Full Text] [Related]
31. Licensed indication for risperidone in dementia.
Phizackerley D
BMJ; 2014 Dec; 349():g7337. PubMed ID: 25498536
[No Abstract] [Full Text] [Related]
32. Treating behavioral and psychological symptoms in patients with psychosis of Alzheimer's disease using risperidone.
Rabinowitz J; Katz I; De Deyn PP; Greenspan A; Brodaty H
Int Psychogeriatr; 2007 Apr; 19(2):227-40. PubMed ID: 16879763
[TBL] [Abstract][Full Text] [Related]
33. Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence.
Aman MG; De Smedt G; Derivan A; Lyons B; Findling RL;
Am J Psychiatry; 2002 Aug; 159(8):1337-46. PubMed ID: 12153826
[TBL] [Abstract][Full Text] [Related]
34. Risperidone effects in the presence/absence of psychostimulant medicine in children with ADHD, other disruptive behavior disorders, and subaverage IQ.
Aman MG; Binder C; Turgay A
J Child Adolesc Psychopharmacol; 2004; 14(2):243-54. PubMed ID: 15319021
[TBL] [Abstract][Full Text] [Related]
35. Risperidone reduces aggression in boys with a disruptive behaviour disorder and below average intelligence quotient: analysis of two placebo-controlled randomized trials.
LeBlanc JC; Binder CE; Armenteros JL; Aman MG; Wang JS; Hew H; Kusumakar V
Int Clin Psychopharmacol; 2005 Sep; 20(5):275-83. PubMed ID: 16096518
[TBL] [Abstract][Full Text] [Related]
36. Report on an open-label prospective study of divalproex sodium for the behavioral and psychological symptoms of dementia as monotherapy and in combination with second-generation antipsychotic medication.
Forester B; Vanelli M; Hyde J; Perez R; Ahokpossi C; Sribney W; Adkison L
Am J Geriatr Pharmacother; 2007 Sep; 5(3):209-17. PubMed ID: 17996660
[TBL] [Abstract][Full Text] [Related]
37. Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia.
Declercq T; Petrovic M; Azermai M; Vander Stichele R; De Sutter AI; van Driel ML; Christiaens T
Cochrane Database Syst Rev; 2013 Mar; (3):CD007726. PubMed ID: 23543555
[TBL] [Abstract][Full Text] [Related]
38. Review: Limited evidence that risperidone reduces aggression and conduct problems in the short term in children and adolescents with disruptive behaviour disorders.
Weiss MD
Evid Based Ment Health; 2013 Aug; 16(3):69. PubMed ID: 23592637
[No Abstract] [Full Text] [Related]
39. Comorbid anxiety and social avoidance in treatment of severe childhood aggression: response to adding risperidone to stimulant and parent training; mediation of disruptive symptom response.
Arnold LE; Gadow KD; Farmer CA; Findling RL; Bukstein O; Molina BS; Brown NV; Li X; Rundberg-Rivera EV; Bangalore S; Buchan-Page K; Hurt EA; Rice R; McNamara NK; Aman MG
J Child Adolesc Psychopharmacol; 2015 Apr; 25(3):203-12. PubMed ID: 25885010
[TBL] [Abstract][Full Text] [Related]
40. A randomized, double-blind, crossover comparison of risperidone and haloperidol in Korean dementia patients with behavioral disturbances.
Suh GH; Son HG; Ju YS; Jcho KH; Yeon BK; Shin YM; Kee BS; Choi SK
Am J Geriatr Psychiatry; 2004; 12(5):509-16. PubMed ID: 15353389
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
